2024
Mechanistic Differences between Torsemide and Furosemide.
Rao V, Cox Z, Ivey-Miranda J, Neville D, Balkcom N, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Tang W, Collins S, Velazquez E, Mentz R, Wilson F, Turner J, Wilcox C, Ellison D, Fang J, Testani J. Mechanistic Differences between Torsemide and Furosemide. Journal Of The American Society Of Nephrology 2024 PMID: 39196651, DOI: 10.1681/asn.0000000000000481.Peer-Reviewed Original ResearchTorsemide groupDiuretic doseTubular site of actionHigher diuretic dosesDose of furosemideProportion of dosesOral furosemideSite of actionPrescribed doseNeurohormonal activationMechanistic substudyClinical outcomesPharmacodynamic advantagesKidney dysfunctionPharmacodynamic parametersKidney functionRandomized trialsNatriuresisTubular sitesFurosemideTorsemideDoseTRANSFORM-HFPlasma volumeBody weightMore Is Better!!
Mehta P, Turner J. More Is Better!! Circulation Cardiovascular Quality And Outcomes 2024, 17: e011063. PMID: 38873760, DOI: 10.1161/circoutcomes.124.011063.Peer-Reviewed Original ResearchSerial direct sodium removal in patients with heart failure and diuretic resistance
Rao V, Ivey‐Miranda J, Cox Z, Moreno‐Villagomez J, Ramos‐Mastache D, Neville D, Balkcom N, Asher J, Bellumkonda L, Bigvava T, Shaburishvili T, Bartunek J, Wilson F, Finkelstein F, Maulion C, Turner J, Testani J. Serial direct sodium removal in patients with heart failure and diuretic resistance. European Journal Of Heart Failure 2024, 26: 1215-1230. PMID: 38556717, DOI: 10.1002/ejhf.3196.Peer-Reviewed Original ResearchConceptsDiuretic resistanceCardiorenal syndromeHeart failureLoop diureticsDiuretic withdrawalHigh-dose loop diureticsN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideGrowth differentiation factor 15Carbohydrate antigen 125Differentiation factor 15Sodium removalRandomized controlled studyCardiorenal parametersDiuretic doseSoluble ST2Natriuretic peptideMedian timeDiuretic responseKidney injuryPeritoneal membraneElectrolyte handlingKidney functionDiureticsInterleukin-6Insulin Requirement and Infrainguinal Bypass Outcomes in Patients with Peripheral Arterial Disease
Alameddine D, Satam K, Slade M, Wang H, Mena-Hurtado C, Turner J, Inzucchi S, Ochoa Chaar C. Insulin Requirement and Infrainguinal Bypass Outcomes in Patients with Peripheral Arterial Disease. Annals Of Vascular Surgery 2024, 102: 25-34. PMID: 38307234, DOI: 10.1016/j.avsg.2023.11.044.Peer-Reviewed Original ResearchInsulin-requiring diabetes mellitusPeripheral arterial diseaseDiabetes mellitusInfrainguinal bypassInsulin requirementsArtery diseaseRisk of MALEBypass surgeryImpact of insulin useRates of primary patencyVascular Quality Initiative databaseOutcomes of patientsPeripheral arterial bypass surgeryInfrainguinal bypass surgeryStratification of patientsCrude rateElevated hemoglobin A1cArtery bypass surgeryAssociation of DMChronic limb-threatening ischemiaIncreased risk of MALEVascular Quality InitiativeLower extremity revascularizationAdverse limb eventsLimb-threatening ischemia
2023
Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects
Rao V, Ivey-Miranda J, Cox Z, Moreno-Villagomez J, Maulion C, Bellumkonda L, Chang J, Field M, Wiederin D, Butler J, Collins S, Turner J, Wilson F, Inzucchi S, Wilcox C, Ellison D, Testani J. Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects. Journal Of The American Society Of Nephrology 2023, 35: 189-201. PMID: 38073038, PMCID: PMC10843196, DOI: 10.1681/asn.0000000000000269.Peer-Reviewed Original ResearchCurrent and Developing Technologies for BP Monitoring
Gunasekaran D, Turner J. Current and Developing Technologies for BP Monitoring. Current Cardiology Reports 2023, 25: 1151-1156. PMID: 37698819, DOI: 10.1007/s11886-023-01956-w.Peer-Reviewed Original ResearchIntravenous Contrast is Associated with AKI in Patients with Stage 1–3 CKD: CON
Turner J. Intravenous Contrast is Associated with AKI in Patients with Stage 1–3 CKD: CON. Kidney360 2023, 5: 648-650. PMID: 37287105, PMCID: PMC11146646, DOI: 10.34067/kid.0000000000000187.Peer-Reviewed Original ResearchDrug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease
Hanna J, Smolderen K, Castro‐Dominguez Y, Romain G, Lee M, Turner J, Mena‐Hurtado C. Drug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease. Journal Of The American Heart Association 2023, 12: e028622. PMID: 36974774, PMCID: PMC10122876, DOI: 10.1161/jaha.122.028622.Peer-Reviewed Original ResearchConceptsEarly-stage chronic kidney diseaseChronic kidney diseaseBare metal stentsDrug-eluting stentsDrug-coated balloonsMortality riskAmputation riskKidney diseaseSevere chronic kidney diseaseMajor amputation riskPlain balloon angioplastyDrug-Coated BalloonAmputation outcomesCKD statusAmputation rateCause mortalityBackground PatientsAdjusted analysisBalloon angioplastyFemoropopliteal interventionsDES useBMS useRegistry dataDisease trialsPatientsCarbon dioxide angiography during peripheral vascular interventions is associated with decreased cardiac and renal complications in patients with chronic kidney disease
Lee S, Ali S, Cardella J, Turner J, Guzman R, Dardik A, Ochoa Chaar C. Carbon dioxide angiography during peripheral vascular interventions is associated with decreased cardiac and renal complications in patients with chronic kidney disease. Journal Of Vascular Surgery 2023, 78: 201-208. PMID: 36948278, DOI: 10.1016/j.jvs.2023.03.029.Peer-Reviewed Original ResearchConceptsAdvanced chronic kidney diseaseChronic kidney diseasePeripheral vascular interventionsContrast volume usagePC-AKICarbon dioxide angiographyCardiac complicationsPropensity matchingKidney diseaseVascular interventionsPost-contrast acute kidney injuryAcute kidney injuryOutcomes of patientsPeripheral arterial diseasePoor renal functionMultivariate logistic regressionLower contrast volumeVolume of contrastCardiac comorbiditiesKidney injuryMinor amputationRenal complicationsRenal functionEndovascular therapyArterial diseaseIn-Hospital Observation on Oral Diuretics After Treatment for Acute Decompensated Heart Failure: Evaluating the Utility
Ivey-Miranda J, Rao V, Cox Z, Moreno-Villagomez J, Mahoney D, Maulion C, Bellumkonda L, Turner J, Collins S, Wilson F, Krumholz H, Testani J. In-Hospital Observation on Oral Diuretics After Treatment for Acute Decompensated Heart Failure: Evaluating the Utility. Circulation Heart Failure 2023, 16: e010206. PMID: 36896716, PMCID: PMC10186250, DOI: 10.1161/circheartfailure.122.010206.Peer-Reviewed Original ResearchConceptsAcute decompensated heart failureDecompensated heart failureDiuretic responseDiuretic dosingOral diureticsHeart failureMulticenter cohortHospital observationLower readmission ratesNet fluid balanceDays postdischargeReadmission ratesHospital readmissionUrine outputReadmission riskFluid statusFluid balanceHospital measuresDose selectionCohortProvider decisionsWeight changeReadmissionDiureticsPatientsUse of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease
Castro-Dominguez Y, Smolderen K, Romain G, Turner J, Mena-Hurtado C. Use of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease. Vascular Medicine 2023, 28: 150-152. PMID: 36710497, DOI: 10.1177/1358863x221148521.Peer-Reviewed Original Research
2022
Predictors of Major Adverse Limb Events After Infrainguinal Bypass in Patients with Diabetes
Alameddine D, Satam K, Slade M, Wang H, Mena-Hurtado C, Turner J, Inzucchi S, Chaar C. Predictors of Major Adverse Limb Events After Infrainguinal Bypass in Patients with Diabetes. American Heart Journal 2022, 254: 241. DOI: 10.1016/j.ahj.2022.10.026.Peer-Reviewed Original ResearchMajor adverse limb eventsLower extremity revascularizationPeripheral artery diseaseAdverse limb eventsInfrainguinal bypassInsulin useDiabetes mellitusLimb eventsVascular Quality Initiative databaseHigher major amputationObjective Diabetes mellitusOutcomes of patientsAssociation of diabetesLower primary patencyMajor risk factorMajor amputationPrimary patencyExtremity revascularizationInsulin therapyKidney transplantArtery diseaseGlucose controlA1c controlRisk factorsHigh riskSafety and Adequacy of Kidney Biopsy Procedure in Patients with Obesity
Qian L, Menez S, Hu D, Weinstein J, Melchinger H, Thiessen-Philbrook H, Luciano R, Turner J, Perazella M, Villalobos C, Shaw M, Wilson F, Parikh C, Moledina D. Safety and Adequacy of Kidney Biopsy Procedure in Patients with Obesity. Kidney360 2022, 4: 98-101. PMID: 36700910, PMCID: PMC10101611, DOI: 10.34067/kid.0006602022.Peer-Reviewed Original Research
2021
OFF-LABEL USE OF DRUG COATED BALLOONS AND STENTS IN PATIENTS WITH FEMOROPOPLITEAL AND ADVANCED CHRONIC KIDNEY DISEASE. INSIGHTS FROM THE VASCULAR QUALITY INITIATIVE
Dominguez Y, Pichert M, Alabi O, Huang J, Qurat-Ul-Ain J, Arham A, Brice A, Ahmed Z, Chaar C, Stacy M, Turner J, Smolderen K, Hurtado C. OFF-LABEL USE OF DRUG COATED BALLOONS AND STENTS IN PATIENTS WITH FEMOROPOPLITEAL AND ADVANCED CHRONIC KIDNEY DISEASE. INSIGHTS FROM THE VASCULAR QUALITY INITIATIVE. Journal Of The American College Of Cardiology 2021, 77: 1012. DOI: 10.1016/s0735-1097(21)02371-8.Peer-Reviewed Original Research
2020
Renal Disease in Older Adults
Turner J, Sharma D. Renal Disease in Older Adults. 2020, 265-276. DOI: 10.1007/978-3-319-47771-8_17.ChaptersCystatin C and Muscle Mass in Patients With Heart Failure
Ivey-Miranda JB, Inker LA, Griffin M, Rao V, Maulion C, Turner JM, Wilson FP, Tang WHW, Levey AS, Testani JM. Cystatin C and Muscle Mass in Patients With Heart Failure. Journal Of Cardiac Failure 2020, 27: 48-56. PMID: 32750487, PMCID: PMC8672303, DOI: 10.1016/j.cardfail.2020.07.013.Peer-Reviewed Original ResearchConceptsHeart failureCreatinine clearanceMuscle massCystatin CHigher muscle massAssociation of eGFRcysGlomerular filtration rateLow muscle massCystatin C levelsAccurate GFR estimationMultivariable analysisFiltration rateEGFRcysEGFRcrBody compositionGFR estimationPatientsCreatinineC levelsClearanceMortalityAssociationShould Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension?
Turner JM, Kodali R. Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension? Current Cardiology Reports 2020, 22: 95. PMID: 32648000, PMCID: PMC7344347, DOI: 10.1007/s11886-020-01352-8.Commentaries, Editorials and LettersConceptsAngiotensin receptor blockersACE inhibitorsEnzyme inhibitorsReceptor blockersSimilar efficacyAngiotensin converting enzyme (ACE) inhibitorsAdverse effectsAnti-hypertensive medicationsManagement of hypertensionUse of ARBGreater side effectsEqual efficacySide effectsClinical scenariosRecent FindingsInClinical settingARBsPrevious trialsEfficacyHypertensionBlockersInhibitorsTrialsAdvantageous effectsMedicationsImpact of Kidney Disease on Peripheral Arterial Interventions: A Systematic Review and Meta-Analysis
Anantha-Narayanan M, Sheikh AB, Nagpal S, Smolderen KG, Turner J, Schneider M, Llanos-Chea F, Mena-Hurtado C. Impact of Kidney Disease on Peripheral Arterial Interventions: A Systematic Review and Meta-Analysis. American Journal Of Nephrology 2020, 51: 527-533. PMID: 32570255, DOI: 10.1159/000508575.Peer-Reviewed Original ResearchConceptsCKD/ESRDCritical limb ischemiaPAD interventionsMajor amputationEarly mortalitySystematic reviewCKD/ESRD patientsPeripheral arterial disease interventionsHigher major amputationOutcomes of patientsPeripheral arterial interventionsSuch comorbid conditionsESRD patientsLimb ischemiaArterial interventionsComorbid conditionsRandomized trialsKidney diseasePatient populationESRDObservational studyRisk populationsFunnel plotPatientsMeta-AnalysisEmpagliflozin in Heart Failure
Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, Suda N, Siwakoti K, Ahmad T, Jacoby D, Riello R, Bellumkonda L, Cox Z, Collins S, Jeon S, Turner JM, Wilson FP, Butler J, Inzucchi SE, Testani JM. Empagliflozin in Heart Failure. Circulation 2020, 142: 1028-1039. PMID: 32410463, PMCID: PMC7521417, DOI: 10.1161/circulationaha.120.045691.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsCotransporter 2 inhibitorsNeurohormonal activationHeart failureRenal dysfunctionBlood volumeHeart failure-related outcomesPlacebo-controlled crossover studyType 2 diabetes mellitusProximal tubular siteHeart failure outcomesStable heart failureUrinary glucose excretionUric acid levelsElectrolyte wastingEmpagliflozin monotherapyOral empagliflozinPlacebo periodStudy drugGlucose excretionNatriuretic effectPotassium wastingTubular sitesDiabetes mellitusFractional excretionReal World Use of Hypertonic Saline in Refractory Acute Decompensated Heart Failure A U.S. Center’s Experience
Griffin M, Soufer A, Goljo E, Colna M, Rao VS, Jeon S, Raghavendra P, D'Ambrosi J, Riello R, Coca SG, Mahoney D, Jacoby D, Ahmad T, Chen M, Tang WHW, Turner J, Mullens W, Wilson FP, Testani JM. Real World Use of Hypertonic Saline in Refractory Acute Decompensated Heart Failure A U.S. Center’s Experience. JACC Heart Failure 2020, 8: 199-208. PMID: 32035891, PMCID: PMC7814403, DOI: 10.1016/j.jchf.2019.10.012.Peer-Reviewed Original ResearchConceptsAcute decompensated heart failureHypertonic saline administrationHypertonic saline therapyHypertonic salineSaline administrationSaline therapyDiuretic efficiencyUrine outputSerum sodiumWeight lossAcute decompensated heartDecompensated heart failureCohort of patientsTotal urine outputReal-world safetyU.S. academic medical centersAcademic medical centerLarge U.S. academic medical centerDiuretic doseCenter experienceHeart failureMetabolic derangementsPrimary analytic approachRespiratory statusClinical variables